Vulvodynia Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Vulvodynia Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The vulvodynia treatment market is expected to register a CAGR of nearly 9% over the forecast period (2022-2027).

The COVID-19 pandemic is an unprecedented health concern and has significantly impacted the vulvodynia treatment market. As per a February 2022 published article titled, "Vulvodynia associated with vulvovaginal microbiome: Neglected due to the COVID-19 pandemic?", the COVID-19 pandemic has posed significant obstacles to clinical practice, oftentimes delaying the management of patients with curable conditions, including urogynecological conditions. Such studies indicate that the number of visits for vulvodynia treatment was reduced during the pandemic, thereby depicting a short-term negative impact on the market. However, with the introduction of vaccines and the upliftment of lockdown restrictions, the market is expected to show healthy growth in the coming period.

Furthermore, the growth of the market is attributed to the factors such as increasing awareness pertaining to vulvodynia, a surge in newer treatment options, growing economic and social impact of vulvodynia, and a rising number of women suffering from vulvodynia.

The rising number of women suffering from vulvodynia is contributing to the increasing demand for vulvodynia treatment. As per a December 2020 published article titled, "Vulvodynia Viewed From a Disease Prevention Framework: Insights From Patient Perspectives," while healthcare provider knowledge and attitudes are often at the forefront of barriers to diagnosis, the study suggests that to minimize patient distress and expedite diagnosis, resources must also be directed to promoting comprehensive sexual health education. In addition, as per a March 2021 published article titled, "The Prevalence and Relevance of Vulvodynia," prevalence estimates derived from population samples are important in understanding the burden of vulvodynia, particularly because it has been estimated that approximately 40–49% of women with chronic vulvar pain do not seek medical care for their pain, therefore leaving clinic-based estimates unreliable and likely dramatically underestimating the true prevalence. As per the same study, large population-based studies of vulvodynia have found that in the general population, roughly 7–10% of women have experienced some type of chronic vulvar pain in their lifetimes, whereas other studies have found somewhat wide-ranging prevalence estimates of up to 16%. In addition, the same source stated that ethnicity has been found to affect population-based estimates of the prevalence of vulvodynia.

However, low awareness pertaining to vulvodynia and the lack of approved products are the major factors hindering the market's growth.

Key Market TrendsLocal Anesthetics Segment is Expected to Hold a Major Market Share in the Vulvodynia Treatment Market

By drug type, local anesthetics are expected to hold a significant share in the vulvodynia treatment market. Local anesthetics restrict the transmission of nerve impulses from the targeted region to the spinal cord. In addition, local anesthetics are much safer to use and have fewer side effects than general anesthetics.

The major factors contributing to the segment's growth are the growing demand for local anesthetics as well as the implementation of strategic initiatives undertaken by the market players. For instance, as per an April 2022 published article titled, "Therapy With Local Anesthetics to Treat Vulvodynia. A Pilot Study", therapy with local anesthetics (TLA) successfully reduced vulvodynia in 36 of 45 patients (80% of responders), and the numeric analog scale (NAS) reduction was from 7.9 to 2.4.

Thus, owing to the above-mentioned factors, the segment is expected to witness significant growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is anticipated to account for a major share of the global vulvodynia treatment market during the forecast period. This is attributed to the increasing incidence of females developing vulvodynia, the presence of key market players, substantial R&D, and health care spending. Moreover, rising vulvodynia awareness, a surge in novel treatment choices, and vulvodynia's expanding economic and social impact is expected to boost the growth of the market within North America.

Within North America, the United States has held a major share of the market. The major factors contributing to the market's growth are the increasing burden of vulvodynia and the increasing demand for vulvodynia treatment. For instance, according to a National Vulvodynia Association article, Harvard research supported by the National Institutes of Health (NIH) found that in 2022, 60% of affected women see three or more doctors before being diagnosed with vulvodynia. Thus, this indicates the rising demand for vulvodynia treatment in the United States, thereby contributing to the market growth.

Moreover, in April 2022, the United States Food and Drug Administration (FDA) approved VIVJOA (oteseconazole capsules), an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.

Thus, due to the above-mentioned factors, the market is estimated to witness significant growth over the forecast period.

Competitive Landscape

The vulvodynia treatment market is competitive with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Eli Lilly and Company, GlaxoSmithKline, Pfizer Inc., Upsher-Smith Laboratories, and Viatris Inc., among other players.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.